ImmuPharma PLC (LON:IMM) drug Lupuzor needs further analysis and certainly isn't a bust, according to Vadim Alexandre, analyst at Northland Capital.
With shares down sharply, the reaction to phase III trial results for the lupus drug has been "knee-jerk" and probably not fully reflective of the outlook for the treatment, he said in an interview with Proactive's Andrew Scott.
Meet 360 Blockchain Inc, Alterola Biotech, Inc, LGC Capital Ltd and BlowFish Technologies at our event,New York, 18 April 2018.Register here >>